Biochemistry and Pharmacology - Research Publications

Permanent URI for this collection

http://hdl.handle.net/11343/214

Filters

2022 1
1
Reset filters

Settings
Statistics
Citations
Start date: 2022 × End date: 2022 × Author: Bozinovski, Steven × Author: McDonald, Christine × Author: Saling, Michael ×

Search Results

Now showing 1 - 1 of 1
  • Item
    No Preview Available
    Novel pharmacological strategies to treat cognitive dysfunction in chronic obstructive pulmonary disease
    Dobric, A ; De Luca, SN ; Spencer, SJ ; Bozinovski, S ; Saling, MM ; McDonald, CF ; Vlahos, R (PERGAMON-ELSEVIER SCIENCE LTD, 2022-05)
    Chronic obstructive pulmonary disease (COPD) is a major incurable global health burden and currently the 3rd largest cause of death in the world, with approximately 3.23 million deaths per year. Globally, the financial burden of COPD is approximately €82 billion per year and causes substantial morbidity and mortality. Importantly, much of the disease burden and health care utilisation in COPD is associated with the management of its comorbidities and viral and bacterial-induced acute exacerbations (AECOPD). Recent clinical studies have shown that cognitive dysfunction is present in up to 60% of people with COPD, with impairments in executive function, memory, and attention, impacting on important outcomes such as quality of life, hospitalisation and survival. The high prevalence of cognitive dysfunction in COPD may also help explain the insufficient adherence to therapeutic plans and strategies, thus worsening disease progression in people with COPD. However, the mechanisms underlying the impaired neuropathology and cognition in COPD remain largely unknown. In this review, we propose that the observed pulmonary oxidative burden and inflammatory response of people with COPD 'spills over' into the systemic circulation, resulting in damage to the brain and leading to cognitive dysfunction. As such, drugs targeting the lungs and comorbidities concurrently represent an exciting and unique therapeutic opportunity to treat COPD and cognitive impairments, which may lead to the production of novel targets to prevent and reverse the debilitating and life-threatening effects of cognitive dysfunction in COPD.